Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 4/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107259 | 0.88 | PROKR2 (0.59) | PROKR2KDM4EACHE | |
| SCHEMBL387975 | 0.88 | PROKR2 (0.63) | PROKR2GRNSORT1KDM4EACHE | |
| SCHEMBL3516623 | 0.88 | PROKR2 (0.63) | PROKR2GRNSORT1KDM4EACHE | |
| SCHEMBL3517508 | 0.88 | PROKR2 (0.63) | PROKR2GRNSORT1KDM4EACHE | |
| SCHEMBL10107277 | 0.87 | PROKR2 (0.59) | PROKR2KDM4E | |
| SCHEMBL3518564 | 0.86 | PROKR2 (0.61) | PROKR2GRNSORT1KDM4EACHE | |
| SCHEMBL565513 | 0.85 | PROKR2 (0.76) | PROKR2GRIN2BGRNSORT1KDM4E | |
| SCHEMBL3517887 | 0.85 | PROKR2 (0.60) | PROKR2GRNSORT1KDM4EACHE | |
| SCHEMBL3517627 | 0.85 | PROKR2 (0.60) | PROKR2GRNSORT1KDM4EACHE | |
| SCHEMBL3518041 | 0.85 | PROKR2 (0.59) | PROKR2GRNSORT1KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885GRIN2B 735/4885GRN 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.